Huabang Life Health Co., Ltd. 2025 Annual Financial Report
In 2025, the company focused on its core pharmaceutical and healthcare business, adhering to the "cautious expansion, reduced financing, deep cultivation, and strong defense" strategy. This approach aimed to enhance core competitiveness, actively undertake various tasks, and continuously improve the operational and management level of all business segments.
I. Audit of the Company's 2025 Financial Statements
(I) The company's 2025 financial statements were audited by Sichuan Huaxin Certified Public Accountants (Special General Partnership), who issued a standard unqualified audit report. The audit opinion stated that the Huabang Health financial statements were prepared in all material respects in accordance with the requirements of the Accounting Standards for Business Enterprises, and fairly reflected the consolidated and parent company's financial position as of December 31, 2025, as well as the consolidated and parent company's operating results and cash flows for 2025.
(II) Key Financial Data and Indicators
In 2025, the company achieved total operating revenue of 1,151,234.72 million yuan, a decrease of 15,232.26 million yuan year-on-year, a decline of 1.31%. Operating profit was 104,658.58 million yuan, an increase of 117,402.08 million yuan year-on-year, a growth of 921.27%. Net profit attributable to shareholders of the listed company was 71,318.83 million yuan, an increase of 101,217.83 million yuan year-on-year, a growth of 338.53%. Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 64,310.90 million yuan, an increase of 98,096.13 million yuan year-on-year, a growth of 290.35%.
| Item | 2025 | 2024 | Year-on-Year Change |
|---|---|---|---|
| Operating Revenue (yuan) | 11,512,347,207.84 | 11,664,669,783.79 | -1.31% |
| Net Profit Attributable to Shareholders of Listed Company (yuan) | 713,188,344.47 | -298,989,917.10 | 338.53% |
| Net Profit Attributable to Shareholders of Listed Company, Net of Non-recurring Items (yuan) | 643,109,024.67 | -337,852,237.08 | 290.35% |
| Net Cash Flow from Operating Activities (yuan) | 2,096,047,419.11 | 1,625,292,850.24 | 28.96% |
| Basic Earnings Per Share (yuan/share) | 0.3615 | -0.1514 | 338.77% |
| Diluted Earnings Per Share (yuan/share) | 0.3615 | -0.1514 | 338.77% |
| Weighted Average Return on Net Assets | 7.24% | -1.85% | 9.09% |
| Item | 2025 | 2024 | Year-End vs. Prior Year Change |
|---|---|---|---|
| Total Assets (yuan) | 29,029,184,016.75 | 29,450,469,334.61 | -1.43% |
| Net Assets Attributable to Shareholders of Listed Company (yuan) | 10,219,770,869.84 | 9,337,058,173.60 | 9.45% |
II. Company Financial Position, Operating Results, and Cash Flow Statement for the Reporting Period
(I) Financial Position